Trial Profile
A retrospective study investigating efficacy of switching from bevacizumab and/or ranibizumab to aflibercept therapy in patients with persistent diabetic macular edema
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Oct 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 17 Oct 2016 New trial record